JCJi-Yoon Choi

Ji-Yoon Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ji-Yoon Choi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PD-L1 mRNA expression correlates with tumor growth rate in giant cell tumor of bone: a volumetric MRI analysis

    by Youngkeun Lee, Ji-Yoon Choi, Min-Jeong Kim, Sung Wook Seo

    Giant cell tumor of bone (GCTB) is a locally aggressive neoplasm with variable biological behavior. Programmed death-ligand 1 (PD-L1) has been implicated i

  • Novel MFSD7‐ATP5I fusion promotes migration and invasion of human sarcoma

    by Jae Woo Shim, Ji‐Yoon Choi, Da Mi Shim, Sung Wook Seo

    Fusion genes have been implicated in the development and progression of several types of sarcomas, serving as valuable diagnostic and prognostic markers, as well as potential therapeutic targets. We discovered a novel major facilitator superfamily domain‐containing 7 (MFSD7) and adenosine triphosphate 5I (ATP5I) gene fusion from sarcomas. In this study, the MFSD7‐ATP5I fusion transcript was screened using RNA sequencing in 55 sarcoma samples and sixteen normal samples. The MFSD7‐ATP5I fusion transcript was detected in 58% of sarcoma samples. The correlation between the expression of MFSD7‐ATP5I fusion transcript and clinicopathological information was analyzed, and MFSD7‐ATP5I expression is associated with marked pleomorphism and lower tumor necrosis. Cell migration and invasion was significantly reduced by knock‐down of MFSD7‐ATP5I. Cell migration and invasion was increased by overexpression of MFSD7‐ATP5I. A phosphokinase assay demonstrated that MFSD7‐ATP5I is involved in the GSK‐3 pathway. The current study found that MFSD7‐ATP5I is associated with increasing pleomorphism and decreasing necrosis of tumors. And our gain and loss of function experiments prove that MFSD7‐ATP5I promotes the invasiveness of tumor cells.